Taking aminoglutethimide markedly reduces the plasma concentrations of Medroxyprogesterone Acetate (LYNDAVEL), possibly through hepatic enzyme-inducing effect. An increase in the dose of Medroxyprogesterone Acetate (LYNDAVEL) is likely to be required.
Medroxyprogesterone Acetate (LYNDAVEL) can influence diabetic control. Adjustment in antidiabetic dosage could be required.
Medroxyprogesterone Acetate (LYNDAVEL) may inhibit ciclosporin metabolism leading to increase plasma-ciclosporin concentration and a risk of toxicity.
Other Services
Country
Account